Literature DB >> 20379157

Roche plans for more convenient-to-use Herceptin and Rituxan.

Mark Ratner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20379157     DOI： 10.1038/nbt0410-298

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Extending the market exclusivity of therapeutic antibodies through dosage patents.

Authors:  Ulrich Storz
Journal:  MAbs       Date:  2016-04-26       Impact factor: 5.857

2.  Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys.

Authors:  Cheng-Ping Mao; Martin R Brovarney; Karim Dabbagh; Herbert F Birnböck; Wolfgang F Richter; Christopher J Del Nagro
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.